Cargando…
P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
Autores principales: | Schavgoulidze, A., Perrot, A., Cazaubiel, T., Leleu, X., Manier, S., Buisson, L., Maheo, S., Do Souto Ferreira, L., Lannes, R., Pavageau, L., Hulin, C., Marolleau, J.-P., Voillat, L., Belhadj, K., Divoux, M., Slama, B., Brechignac, S., Macro, M., Stoppa, A.-M., Sanhes, L., Orsini-Piocelle, F., Fontan, J., Chretien, M.-L., Demarquette, H., Mohty, M., Avet-Loiseau, H., Corre, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430506/ http://dx.doi.org/10.1097/01.HS9.0000846368.66738.8f |
Ejemplares similares
-
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
por: Schavgoulidze, Anaïs, et al.
Publicado: (2023) -
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020) -
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022) -
Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021) -
P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
por: Macro, M., et al.
Publicado: (2022)